Table 3.
Treatment characteristics of the population of LTFU and patients with SVR assessment
| Parameter | LTFU, n=509 | Patients with SVR assessment, n=18,354 | p |
|---|---|---|---|
| Treatment-naïve, n (%) | 435 (85.5) | 14,807 (80.7) | 0.007 |
| Genotype-specific treatment regimens, n (%) | 167 (32.8) | 9646 (52.6) | <0.0001 |
| ASV+DCV | 3 (0.6) | 132 (0.7) | >0.99 |
| OBV/PTV/r+DSV±RBV | 49 (9.6) | 3998 (21.8) | <0.0001 |
| LDV/SOF±RBV | 61 (12) | 2981 (16.2) | 0.0099 |
| GZR/EBR±RBV | 54 (10.6) | 2536 (13.8) | 0.0380 |
| SOF±SMV±RBV | 0 | 10 (0.1) | >0.99 |
| Pangenotypic regimens, n (%) | 342 (67.2) | 8708 (47.4) | <0.0001 |
| SOF+RBV | 30 (5.9) | 311 (1.7) | <0.0001 |
| SOF+DCV±RBV | 3 (0.6) | 43 (0.2) | 0.13 |
| GLE/PIB | 140 (27.5) | 4777 (26.0) | 0.45 |
| GLE/PIB+SOF+RBV | 0 | 7 (<0.1) | >0.99 |
| SOF/VEL±RBV | 164 (32.2) | 3476 (18.9) | <0.0001 |
| SOF/VEL/VOX | 5 (1.0) | 83 (0.5) | 0.09 |
| RBV-containing regimens, n (%) | 64 (12.6) | 2579 (14.1) | 0.343 |
Abbreviations: ASV asunaprevir, DCV daclatasvir, DSV dasabuvir, EBR elbasvir, GLE glecaprevir, GT genotype, GZR grazoprevir, LDV ledipasvir, LTFU loss to follow-up, OBV ombitasvir, PIB pibrentasvir, PTV/r paritaprevir boosted with ritonavir, RBV ribavirin, SMV simeprevir, SOF sofosbuvir, SVR sustained virological response, VEL velpatasvir, VOX voxilaprevir